Depixus Raises EUR 30.6M (USD 35.4M) in Collection A Financing

Depixus®, a biotechnology firm growing a novel expertise for the quick, correct, and simple extraction of multiomic info from DNA, RNA, and proteins, at the moment proclaims it has raised EUR 30.6 million in an oversubscribed Collection A financing. The funds will likely be used to additional develop its proprietary MAGNA™ instrument system, workflows, and reagents in the direction of business launch. 

The spherical was co-led by Lansdowne Companions and the PSIM Fund operated by Bpifrance on behalf of the French State, with participation by Casdin Capital, and present traders, together with Arix Bioscience. This financing brings the corporate’s whole fairness and grant funding to-date to over EUR 41 million (USD 47 million).

With MAGNA™, massive numbers of particular person molecules of DNA and RNA are captured of their native kind, immobilised inside a circulate cell, and are then out there for repeated interrogations that may reveal a broad vary of options together with base modifications, molecular construction, and interactions with different nucleic acids, proteins, or medicine. These capabilities unlock beforehand unattainable insights into the “dynamic genome” – the layers of data past the four-base coding sequences of DNA and RNA, which are key to gene expression, regulation, and management.

Detection of irregular modifications in base modification patterning have been proven to underpin many illness processes. The MAGNA™ expertise will vastly speed up entry to this complicated layer of the dynamic genome, opening up vital alternatives within the earlier detection and improved administration of main illnesses akin to most cancers.  Furthermore, the way in which during which nucleic acids, particularly RNA, are folded and structured can be crucial to organic regulation. With MAGNA™ these buildings can usually be revealed and analysed intimately.  MAGNA™ subsequently has robust potential as an assist within the discovery of medication that both disrupt or stabilise RNA buildings – affording alternatives to modulate hitherto ‘undruggable’ pathological mobile processes.

We’re extraordinarily excited by the facility of our MAGNA expertise to beat the present challenges of base modification sequencing and RNA structural evaluation. Our expertise seems set to open new horizons in purposes akin to biomarker discovery for liquid biopsy most cancers detection, virology, and the event of medication focusing on RNA.

We’re more than happy to draw such a robust group of traders, which additional validates the potential of the MAGNA platform to remodel our understanding of mobile processes. Because of the help from our new and present traders, we’ll proceed to recruit extra high expertise in France and the UK to additional develop the platform by way of to business launch and past.” 

Gordon Hamilton, CEO and Co-founder of Depixus

John Berriman, Chairman of Depixus, mentioned: “Depixus has grown by leaps and bounds since its inception.  We at the moment are assured that MAGNA devices will present distinctive and economical insights into the event and therapy of illness.

This can be a very thrilling time for the Firm because it progresses from pre-commercial analysis in the direction of the launch of merchandise.” 

Lachlan MacKinnon, Board member and consultant of Lansdowne commented: “I’m actually excited to affix the Board of Depixus at this crucial second within the firm’s historical past.

The Depixus expertise will allow scientists and biotechnology firms to maneuver from a world of measuring DNA and RNA as linear, one-dimensional sequences, to certainly one of dynamic, three-dimensional objects with many base modifications, at scale.

Having seen the affect of methylation detection on liquid biopsy, I sit up for the corporate making sizeable contributions throughout the broader dynamic genomics panorama”.

We’re delighted to accomplice with Lansdowne to help Depixus within the improvement of its MAGNA instrumentation system. The corporate is a laureate of the ultimate section of France’s Worldwide Innovation Problem. Depixus has confirmed the excellence of its breakthrough expertise for the quick, correct and simple extraction of data from DNA and RNA molecules past their easy sequence. This opens the door for a lot of purposes akin to earlier and extra correct most cancers prognosis.” 

Thibaut Roulon, Senior Funding Director at Bpifrance

Following this capital increase, Lachlan MacKinnon and Thibaut Roulon, will be part of Mark Chin of Arix Bioscience, Ronald Lindsay, Steve Allen, Gordon Hamilton, and John Berriman, on the Board of Administrators.

The corporate relies in Paris, France and Cambridge, UK, and is actively recruiting high expertise to affix its staff.

Depixus® just lately introduced the publication of a scientific paper showcasing the MAGNATM capabilities within the peer-reviewed journal Communications Biology, a part of Nature Analysis journals. The paper, entitled ‘Detection of genetic variation and base modifications at base-pair decision on each DNA and RNA’, will be freely downloaded right here.

About Depixus® and MAGNA™

Depixus® is a fast-growing revolutionary biotechnology firm based mostly in Paris, France, and Cambridge, UK, growing its cutting-edge MAGNA™ expertise to disclose the secrets and techniques of the dynamic genome. The expertise is ready to remodel our understanding of how genetics is regulated and supply highly effective new insights into the mechanisms of illness.

Depixus® is a spin-out from spin-out from Ecole Normale Supérieure (ENS), one of the vital prestigious ‘grandes écoles’ in France. The corporate has been financed not solely by way of fairness funding but additionally through quite a few grants, together with from the EU’s Horizon 2020 SME Instrument and Innovate UK programmes.

The MAGNA™ expertise relies on an instrument system referred to as a ‘magnetic lure’. Samples of nucleic acid are captured inside a circulate cell after which will be analysed at a number of ranges of decision. To be taught extra about the way in which the MAGNA™ expertise works and among the many alternative assays that may be carried out with the platform, please go to www.depixus.com.

#Depixus #Raises #EUR #306M #USD #354M #Collection #Financing